The Effects of Resveratrol on Endometriosis

Effects of Resveratrol on expression of inflammatory factors and progestrone receptors in endometrium of women with endometriosis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015101724569N1

Enrollment

Registered

2016-05-31

Start date

2016-06-30

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis. Endometriosis

Interventions

Intervention 1: Control group: Consist of the endometrium of infertile women with Endometriosis. They will take routine treatment and placebo (12 week). Intervention 2: Intervention group: Consist of

Placebo

Treatment - Drugs

Control group: Consist of the endometrium of infertile women with Endometriosis. They will take routine treatment and placebo (12 week)

Intervention group: Consist of the endometrium of infertile women with Endometriosis. They will take routine treatment and resveratrol capsule 1000 mg/ daily for 12 week.

Eligibility

Sex/Gender

Female

Age

18 Years to 37 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: No usage of hormonal drugs; hormonal contraceptives; IUDs and supplements during the last three months before the first biopsy; no contraindication of resveratrol such as allergy to grape and green tea; no current suffering from autoimmune or known intestinal diseases; no history of pregnancy or lactation during the last 3 months;Age 18-37 years old; Body mass index between 18.5 to 30 kilograms per square meter.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Experission of VEGF gene. Timepoint: Before and after intervention. Method of measurement: RT-PCR.;Experission of MMP9 gene. Timepoint: Before and after intervention. Method of measurement: RT-PCR.;Experission of MMP2 gene. Timepoint: Before and after intervention. Method of measurement: RT-PCR.;Experission of the PRb gene and protein. Timepoint: Before and after intervention. Method of measurement: Western Blot and RT-PCR.;Experission of the PRA gene and protein. Timepoint: Before and after intervention. Method of measurement: Western Blot and RT-PCR.;Experission of IL1b gene and protein. Timepoint: Before and after intervention. Method of measurement: Western Blot and RT-PCR.;Experission of IL8 gene. Timepoint: Before and after intervention. Method of measurement: RT-PCR.;Experission the gene and TNF alpha protein. Timepoint: Before and after intervention. Method of measurement: Western Blot and RT-PCR.	—

Measure

Time frame

Experission of VEGF gene. Timepoint: Before and after intervention. Method of measurement: RT-PCR.;Experission of MMP9 gene. Timepoint: Before and after intervention. Method of measurement: RT-PCR.;Experission of MMP2 gene. Timepoint: Before and after intervention. Method of measurement: RT-PCR.;Experission of the PRb gene and protein. Timepoint: Before and after intervention. Method of measurement: Western Blot and RT-PCR.;Experission of the PRA gene and protein. Timepoint: Before and after intervention. Method of measurement: Western Blot and RT-PCR.;Experission of IL1b gene and protein. Timepoint: Before and after intervention. Method of measurement: Western Blot and RT-PCR.;Experission of IL8 gene. Timepoint: Before and after intervention. Method of measurement: RT-PCR.;Experission the gene and TNF alpha protein. Timepoint: Before and after intervention. Method of measurement: Western Blot and RT-PCR.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahshad Khodarahmian

Tehran University of Medical Sciences

m-khodarahmian@razi.tums.ac.ir+98 21 6641 9072

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026